Press Releases

YEAR
Toggle Summary Nabriva Announces Closing of Rights Offering and Underwritten Offering
VIENNA, Austria and KING OF PRUSSIA, Pa. , Dec. 19, 2016 (GLOBE NEWSWIRE) -- (NASDAQ:NBRV) – Nabriva Therapeutics Plc announced today the closing of its previously announced rights offering for up to 588,127 common shares, including common shares represented by American Depositary Shares (ADSs), to
View HTML
Toggle Summary Nabriva Announces Results of Rights Offering and Pricing of Underwritten Offering
VIENNA, Austria and KING OF PRUSSIA, Pa. , Dec. 14, 2016 (GLOBE NEWSWIRE) -- (NASDAQ:NBRV) – Nabriva Therapeutics Plc announced today the completion of its previously announced rights offering for up to 588,127 common shares, including common shares represented by American Depositary Shares (ADSs),
View HTML
Toggle Summary Nabriva Announces Terms of Rights Offering
VIENNA, Austria and KING OF PRUSSIA, Pa. , Nov. 29, 2016 (GLOBE NEWSWIRE) -- Nabriva Therapeutics Plc (NASDAQ:NBRV) announced today the terms of its rights offering for up to 588,127 common shares, including common shares represented by American Depositary Shares (ADSs), to its existing common
View HTML
Toggle Summary Nabriva Announces Change in Record Date for Planned Rights Offering
VIENNA, Austria and KING OF PRUSSIA, Pa. , Nov. 22, 2016 (GLOBE NEWSWIRE) -- Nabriva Therapeutics Plc  (Nabriva) (NASDAQ:NBRV), an Austrian stock corporation, announced today that it has changed the record date for its previously announced planned rights offering from November 22, 2016 to November
View HTML
Toggle Summary Nabriva Reports Third Quarter 2016 Financial Results
Reiterates expectation of top-line data from both CABP phase 3 trials in the second half of 2017. VIENNA, Austria and KING OF PRUSSIA, Pa. , Nov. 16, 2016 (GLOBE NEWSWIRE) -- (NASDAQ:NBRV) – Nabriva Therapeutics AG , a clinical stage biopharmaceutical company engaged in the research and development
View HTML
Toggle Summary Nabriva Announces Planned Rights Offering and Sets Record Date
VIENNA, Austria and KING OF PRUSSIA, Pa. , Nov. 11, 2016 (GLOBE NEWSWIRE) -- Nabriva Therapeutics AG (Nabriva) (NASDAQ:NBRV), an Austrian stock corporation, announced today that it plans to raise additional capital through a rights offering. The record date of the rights offering will be November
View HTML
Toggle Summary Nabriva Presents Research on Lefamulin at IDWeek 2016™
Presentations Support IV and Oral Dosing Selection in Lefamulin’s Ongoing Phase 3 Clinical Development Program VIENNA, Austria and KING OF PRUSSIA, Pa. , Oct. 31, 2016 (GLOBE NEWSWIRE) -- Nabriva Therapeutics AG (NASDAQ:NBRV), a clinical-stage biopharmaceutical company engaged in the research and
View HTML
Toggle Summary Nabriva Announces Presentations at Upcoming IDWeek 2016
VIENNA, Austria and KING OF PRUSSIA, Pa. , Oct. 20, 2016 (GLOBE NEWSWIRE) -- Nabriva Therapeutics AG (NASDAQ:NBRV), a clinical stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class
View HTML
Toggle Summary Nabriva to Present at the Rodman & Renshaw 18th Annual Global Investment Conference
VIENNA, Austria and KING OF PRUSSIA, Pa. , Sept. 06, 2016 (GLOBE NEWSWIRE) -- Nabriva Therapeutics AG (NASDAQ:NBRV), a clinical stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class
View HTML
Toggle Summary Nabriva to Present at the 2016 Wedbush PacGrow Healthcare Conference
VIENNA, Austria and KING OF PRUSSIA, Pa. , Aug. 10, 2016 (GLOBE NEWSWIRE) -- Nabriva Therapeutics AG (NASDAQ:NBRV), a clinical stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class
View HTML

For Media Inquiries

PR@nabriva.com


For Investor Relations

David Garrett
Vice President, Corporate Controller and Head of Investor Relations
Nabriva Therapeutics plc

E-mail: david.garrett@nabriva.com